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Effects of connexin-mimetic peptides on nitric oxide synthase- cyclin are the best characterized vasodilator factors pro-
and cyclooxygenase-independent renal vasodilation. duced by the endothelium. Over the past two decades,
Background. Research on the physiological role of endothe- several lines of evidence have convincingly demonstratedlium-derived hyperpolarizing factor (EDHF) is hampered by
the existence of a third endothelium-derived vasodilatorthe persistent controversy on its nature and mechanisms of ac-
pathway, which is especially prominent in resistance ar-tion, as well as by the lack of specific inhibitors that are suitable
for in vivo use. Recent in vitro studies support a role for gap teries [1, 2]. Since the NO synthase- and cyclooxygenase-
junctions in EDHF-mediated signal transmission. The present independent endothelium-mediated vasodilation is asso-
study examines the contribution of gap junctional communica- ciated with vascular smooth muscle hyperpolarization, thetion to the EDHF-mediated responses in the rat renal microcir-
term endothelium-derived hyperpolarizing factor (EDHF)culation in vivo and addresses the physiological role of EDHF.
was proposed [3]. The nature of EDHF is one of theMethods. The effects of intrarenal administration of con-
nexin-mimetic peptides on the L-NAME- and indomethacin- most contentious questions in vascular physiology [4].
resistant renal blood flow (RBF) response to acetylcholine, on Current evidence suggests that EDHF is more than one
basal RBF and on systemic blood pressure were examined. substance and that the identity, as well as the mechanismsResults. 43Gap 27, a peptide homologous to the second extra-
of action of EDHF show substantial tissue and speciescellular loop of connexin 43, partially inhibited the L-NAME-
heterogeneity. Several candidate mediators have beenand indomethacin-resistant RBF response to acetylcholine,
whereas 40Gap 27, homologous to the second extracellular loop proposed, including epoxyeicosatrienoic acids (EETs),
of connexin 40, abolished the response. A control peptide, with which are cytochrome P450 mono-oxygenase derived
a replacement of two amino acids in the motif SRPTEK present metabolites of arachidonic acid [5–7], the endogenousin the second extracellular loop of connexins 40 and 43, was
cannabinoid anandamide [8], and potassium ions [9]. Inwithout effect. None of the peptides affected the response to
some vessels, however, neither a cytochrome P450 me-DETA-NONOate, pinacidil or papaverine. Intrarenal infusion
of 43Gap 27 or 40Gap 27 decreased basal RBF and increased tabolite nor a cannabinoid or potassium meets the phar-
mean arterial blood pressure, both in the presence and absence macological criteria for an EDHF. Except for the
of systemic infusion of L-NAME and indomethacin. involvement of opening of K-channels on endothelialConclusions. Inhibition of gap junctional communication
and/or smooth muscle cells, the mechanisms of thewith connexin-mimetic peptides blocks EDHF-mediated sig-
EDHF-pathway are still a matter of debate.nal transmission in vivo, as suggested by the abolishment of
L-NAME- and indomethacin-resistant renal vasodilation. The Although both cascade bioassay [10] and sandwich
peptides also decrease basal RBF and increase blood pressure, preparations [11] have suggested that EDHF can diffuse
supporting a role for tonic EDHF release in the control of tis- freely in the extracellular space, several lines of evidencesue perfusion and vascular resistance.
support the direct transfer of EDHF through myoendo-
thelial gap junctions. Functional dye transfer experi-
ments demonstrate direct coupling between endothelialThe vascular endothelium synthesizes and releases
cells and the underlying smooth muscle cells [12]. Hyper-vasoactive autacoids that regulate vascular smooth mus-
polarization of the smooth muscle cells is associated withcle tone and reactivity. Nitric oxide (NO) and prosta-
hyperpolarization of the endothelial cells, supporting
electrical coupling between the two cell types. Recently,
myoendothelial gap junction plaques were demonstratedKey words: connexins, EDHF, gap junctions, renal microcirculation,
blood flow, hypertension, signal transmission. anatomically and appeared substantially more common
in the distal than in the proximal regions of the vascula-Received for publication April 23, 2001
ture [13]. This finding is commensurate with the well-and in revised form August 16, 2001
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sel size becomes smaller [14–18]. Finally, gap junction Belgium), receiving care in accordance with NIH and
national guidelines for animal protection. The rats wereblockers inhibit NO synthase- and cyclooxygenase-
anesthetized with thiobutabarbital (100 mg/kg i.p.; Inac-independent relaxation in different artery types in vitro
tin; RBI, Natick, MA, USA). The trachea was intubated,[19–25].
a jugular vein was cannulated for continuous infusion ofGap junctions are formed when two connexons con-
isotonic saline (3 mL/h) and administration of drugs, andtributed by neighboring cells dock through interactions
a carotid artery was cannulated for continuous monitor-between their extracellular loops. A connexon consists
ing of arterial blood pressure and recording of heart rate.of six connexins arranged around an aqueous central
The right renal and suprarenal arteries were exposed viapore, that allows the transfer of electrical current and
a small abdominal incision. The suprarenal artery was can-small molecules 1 kD in size. Multiple gap junctions,
nulated for intrarenal administration of drugs. A bloodin turn, cluster to form gap junction plaques [26]. Despite
flow sensor with an inner diameter of 0.6 to 0.8 mm wasthe large number of connexins identified, only connexin
placed on the renal artery, allowing continuous renal43, 40 and 37 are expressed in mammalian vasculatures
blood flow monitoring by an electromagnetic square[27]. Several pharmacological agents interfere with gap
wave flow meter (Skalar Medical, Delft, The Nether-junction formation, including heptanol, the 18 and 18
lands) [18].isoforms of glycyrrhetinic acid and carbenoxolone, but
these molecules may have unwanted aspecific effects Experimental protocols
when used in vivo. The use of connexin knockout mice
Series 1. All studies were performed in the continuous
[28] or of connexin-mimetic peptides [20–25] may be and combined presence of systemic NO synthase and
more specific means to interfere with gap junction func- cyclooxygenase blockade: L-NG-nitroarginine methyl-
tion. Connexin-mimetic peptides possess sequence ho- ester HCl (L-NAME; 10 mg/kg bolus followed by 20
mology to specific regions of connexin proteins. The mg/kg/h; Sigma Chemical Co, St. Louis, MO, USA) and
interactions between the extracellular loops of connexins indomethacin (4 mg/kg bolus followed by 8 mg/kg/h;
are not fixed and immobile, but involve a dynamic dock- Sigma).
ing-undocking mechanism. The connexin-mimetic pep- The renal blood flow response to intrarenal acetylcho-
tides bind to the essential components of the connexin line (1 to 50 ng in bolus; Sigma), to the NO donor deta-
docking sites and thus interfere with the docking of two NONOate (16 to 80 g in bolus; Alexis, Gru¨nberg, Ger-
connexons contributed by neighboring cells. many), to the K-channel opener pinacidil (25 to 125 g
Very little research concerning EDHF has been con- in bolus; Sigma) and to papaverine (10 to 50 g in bolus;
ducted in vivo, reflecting the toxicity of potassium chan- Federa, Brussels, Belgium) was examined before and 5
nel blocking agents and the inability to directly mea- and 30 minutes after infusion of 43Gap 27 peptide (3.91
sure endothelium-dependent hyperpolarization, as the mg, sequence SRPTEKTIFII; synthesized by Sigma-
hallmark of EDHF activity. Nevertheless, in vivo mea- Genosys (Cambridge, UK); N  8), 40Gap 27 peptide
surement of the contribution of EDHF to endothe- (3.87 mg, sequence SRPTEKNVFIV; N  6), a control
lium-dependent vasodilation may be important, as the peptide (3.62 mg, sequence SRGGEKNVFIV; N  6)
magnitude of the response is determined by the resting or solvents (1 mL 1% bovine serum albumin in solvent;
membrane potential, which is quite different in arteries N  6).
under physiological pressure in vivo than in those sus- Before administration of the next dose of acetylcho-
pended in vitro [29]. Furthermore, in vivo research per- line, detaNONOate, papaverine and pinacidil, renal
mits the investigation of the physiological relevance of blood flow was allowed to return to baseline values. The
EDHF, which is currently unknown. doses and timing of administration of the pharmacologi-
The aim of the present study was to characterize the cal agents were determined in pilot experiments. The
NO synthase- and cyclooxygenase-independent endo- upper limit of the dose-response curve to acetylcholine,
detaNONOate, papaverine and pinacidil was chosen asthelium-mediated vasodilation in response to acetylcho-
the highest dose that was devoid of systemic blood pres-line in the renal microcirculation in vivo. In particular,
sure effects. The dose of the connexin-mimetic peptidesthe potential contribution of gap junctional communica-
was selected as the lowest dose that achieved the maxi-tion to the EDHF-response was evaluated by the use of
mal effect. Time-response curves showed that the effectconnexin-mimetic peptides. In addition, the physiologi-
of the peptides was maximal after five minutes and gener-cal role of EDHF was addressed by evaluating the effects
ally disappeared after 30 minutes.of blockade of EDHF-mediated responses on basal renal
Series 2. The renal blood flow response to intrarenalblood flow and on systemic blood pressure.
acetylcholine, detaNONOate, pinacidil and papaverine
was examined before and 5 and 30 minutes after infusion
METHODS of 40Gap 27 peptide (N  6) or control peptide (N 
The studies were performed in 38 female Wistar rats 6). The experiments were performed in the absence of
systemic NO synthase and cyclooxygenase blockade.with a body weight of 250 g (Iffa Credo, Brussels,
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Fig. 1. Representative trace of a dose-response
curve to acetylcholine (ACh) before and after
administration of 40Gap 27 peptide. The exper-
iment was performed in the continuous and
combined presence of systemic nitric oxide
(NO) synthase and cyclooxygenase blockade.
Fig. 2. The renal blood flow increase in re-
sponse to intrarenal acetylcholine after intra-
venous L-NAME and indomethacin before
(), 5 min after (), and 30 min after () intra-
renal infusion of a connexin-mimetic peptide.
(A) 43Gap 27 peptide (N  8), *P  0.05 vs.
baseline (B) 40Gap 27 peptide (N  6), *P 
0.01 vs. baseline; (C) control peptide (N  6);
(D) solvent (N 6). The area under the curve
(AUC) of the change from baseline values
was calculated for each bolus acetylcholine
and the data are expressed as mean  SEM.
Statistical analysis Infusion of 40Gap27, which is homologous to the sec-
ond extracellular loop of connexin 40, abolished theThe data are presented as mean  SEM. The renal
L-NAME- and indomethacin-resistant renal vasodilata-blood flow response to the different agonists is expressed
tion to acetylcholine five minutes after infusion (Fig. 1).as the area under the curve of the change in renal blood
The response almost completely recovered 30 minutesflow (mL/minmin), as detailed previously [18]. Analy-
after infusion of the peptide. A control peptide, with asis of variance, paired and unpaired t tests were used as
replacement of two animo acids in the motif SRPTEKappropriate. The significance level was set at P  0.05.
present in the second extracellular loop of connexins
40 and 43, was without effect on the vasodilation to
RESULTS acetylcholine (Fig. 2). The L-NAME- and indomethacin-
Effects on the NO synthase- and cyclooxygenase- resistant vasodilatation to acetylcholine remained stable
independent renal vasodilation to acetylcholine over time after infusion of solvent without connexin-
mimetic peptide (Fig. 2).Intrarenal infusion of 43Gap27, a short peptide possess-
ing conserved sequence homology to part of the second
Effects on the renal vasodilatation to acetylcholine inextracellular loop of connexin 43, partially inhibited the
the absence of systemic NO synthase- andL-NAME- and indomethacin-resistant renal blood flow
cyclooxygenase-blockaderesponse to acetylcholine, when it was evaluated five
In the absence of L-NAME and indomethacin, intra-minutes after administration of the peptide (Figs. 1 and
renal infusion of 40Gap27 decreased the renal vasodila-2). The renal blood flow response recovered to baseline
tion to acetylcholine five minutes after infusion (Fig. 3).values, when the dose-response curve to acetylcholine
was repeated 30 minutes after infusion of the peptide. The response to acetylcholine recovered to baseline val-
De Vriese et al: Connexin-mimetic peptides180
Fig. 3. The renal blood flow increase in re-
sponse to intrarenal acetylcholine in the ab-
sence of L-NAME and indomethacin before
(), 5 min after () and 30 min after ()
intrarenal infusion of a connexin-mimetic pep-
tide. (A) 40Gap 27 peptide (N  6), *P  0.05
vs. baseline; (B) control peptide (N  6). The
area under the curve (AUC) of the change
from baseline values was calculated for each
bolus of acetylcholine and the data are ex-
pressed as mean  SEM.
Fig. 4. The renal blood flow increase in re-
sponse to intrarenal DETA-NONOate after
intravenous L-NAME and indomethacin be-
fore (), 5 min after () and 30 min after
() intrarenal infusion of a connexin-mimetic
peptide. (A) 43Gap 27 peptide (N  8); (B)
40Gap 27 peptide (N  6); (C) control peptide
(N  6); (D) solvent (N  6). The area under
the curve (AUC) of the change from baseline
values was calculated for each bolus DETA-
NONOate and the data are expressed as
mean  SEM.
ues 30 minutes after infusion of the peptide. The control Effects on basal renal blood flow, mean arterial blood
pressure and heart ratepeptide did not affect the renal blood flow response to
acetylcholine (Fig. 3). Basal renal blood flow was not different between the
treatment groups: 4.73  0.21 mL/min (5.31  0.17
Effects on the renal vasodilation to DETA-NONOate, mL/min/g kidney weight) in the 43Gap27 group, 4.47 
pinacidil and papaverine 0.25 mL/min (5.30  0.28 mL/min/g kidney weight) in
43Gap27, 40Gap27 and the control peptide did not affect the 40Gap27 group, 4.05 0.19 mL/min (5.04 0.35 mL/
the renal vasodilation to DETA-NONOate, pinacidil min/g kidney weight) in the control peptide group and
and papaverine when tested under conditions of systemic 4.28  0.33 mL/min (5.14  0.47 mL/min/g kidney
NO synthase and cyclooxygenase blockade (Figs. 4, 5 weight) in the solvents group (P	 0.05 between groups).
and 6). The vasodilation to DETA-NONOate, pinacidil Renal blood flow decreased significantly after systemic
and papaverine remained stable over time after infusion L-NAME and indomethacin infusion and to a similar
of solvent without connexin-mimetic peptide (Figs. 4–6). extent in all treatment groups: 29.5 2.2% in the 43Gap27
40Gap27 and the control peptide did not alter the renal group, 30.4  5.0% in the 40Gap27 group, 34.3  3.0%
vasodilation to DETA-NONOate, pinacidil and papav- in the control peptide group and 26.7  4.9% in the
erine, measured in the absence of L-NAME and indo- solvents group (P 	 0.05 between groups; Fig. 7). Infu-
sion of 43Gap27 caused a mild but significant decreasemethacin (data not shown).
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Fig. 5. The renal blood flow increase in re-
sponse to intrarenal pinacidil after intrave-
nous L-NAME and indomethacin before (),
5 min after () and 30 min after () intrarenal
infusion of a connexin-mimetic peptide. (A)
43Gap 27 peptide (N 8); (B) 40Gap 27 peptide
(N  6); (C) control peptide (N  6); (D)
solvent (N  6). The area under the curve
(AUC) of the change from baseline values
was calculated for each bolus pinacidil and
the data are expressed as mean  SEM.
Fig. 6. The renal blood flow increase in re-
sponse to intrarenal papaverine after intrave-
nous L-NAME and indomethacin before (),
5 min after () and 30 min after () intrarenal
infusion of a connexin-mimetic peptide. (A)
43Gap 27 peptide (N 8); (B) 40Gap 27 peptide
(N  6); (C) control peptide (N  6); (D)
solvent (N  6). The area under the curve
(AUC) of the change from baseline values
was calculated for each bolus papaverine and
the data are expressed as mean  SEM.
of basal renal blood flow, in addition to the fall caused by renal blood flow recovered to pre-treatment values. In
contrast, infusion of the control peptide or of the solventcombined NO synthase- and cyclooxygenase-blockade.
After intrarenal administration of 40Gap27, a more pro- did not affect renal blood flow (Fig. 7).
Baseline mean blood pressure was not different be-nounced decrease of basal renal blood flow was ob-
served. Thirty minutes after infusion of the peptides, tween the treatment groups: 123.4  3.7 mm Hg in the
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Fig. 7. Renal blood flow (RBF) in baseline
conditions (), after intravenous administra-
tion of L-NAME with indomethacin ( ), 5
min after intrarenal infusion of a connexin-
mimetic peptide () and 30 min after the infu-
sion of the peptide ( ). (A) 43Gap 27 peptide
(N  8); (B) 40Gap 27 peptide (N  6); (C)
control peptide (N  6); (D) solvent (N  6).
*P  0.001 vs. baseline values, #P  0.001 vs.
after L-NAME with indomethacin, §P  0.02
vs. 5 min after the peptide.
Fig. 8. Mean arterial blood pressure (BP) in
baseline conditions (), after intravenous ad-
ministration of L-NAME with indomethacin
( ), 5 min after intrarenal infusion of a con-
nexin-mimetic peptide (), and 30 min after
the infusion of the peptide ( ). (A) 43Gap 27
peptide (N  8); (B) 40Gap 27 peptide (N 
6); (C) control peptide (N  6); (D) solvent
(N  6). *P  0.01 vs. baseline values, #P 
0.01 vs. after L-NAME with indomethacin,
§P  0.01 vs. 5 min after the peptide.
43Gap27 group, 115.8 4.3 mm Hg in the 40Gap27 group, not induce alterations in heart rate: the heart rate was
318 4.9/min and 328 3.7/min before and after 40Gap27,116.0  2.2 mm Hg in the control peptide group, and
125.8  13.6 mm Hg in the solvents group (P 	 0.05 respectively, and 300  13.7/min and 293  11.2/min be-
fore and after the control peptide, respectively.between groups). Concomitant systemic infusion of
L-NAME and indomethacin increased mean arterial
blood pressure significantly and to a similar extent in the
DISCUSSIONdifferent treatment groups: 23.4  4.6% in the 43Gap27
In the renal microcirculation of the rat, a large residualgroup, 26.8  3.5% in the 40Gap27 group, 23.9  6.0%
response to acetylcholine is present after combined high-in the control peptide group and 16.5  4.6% in the
dose NO synthase- and cyclooxygenase inhibition, assolvents group (P 	 0.05 between groups; Fig. 8). Infu-
described previously [18]. A short peptide homologoussion of 43Gap27 caused a mild but significant increase of
to a sequence in the second extracellular loop of con-systemic blood pressure, in addition to the rise caused by
nexin 40 is a potent inhibitor of the NO synthase- andcombined NO synthase- and cyclooxygenase-blockade.
cyclooxygenase-independent acetylcholine-induced va-After intrarenal administration of 40Gap27, a significant
sodilation in the kidney. A peptide homologous to therise of systemic blood pressure was observed. Thirty
extracellular loop of connexin 43 also inhibits the NOminutes after infusion of the peptides, blood pressure
synthase- and cyclooxygenase-independent acetylcho-fell to values similar to those before administration of
line-induced vasodilation, but to a lesser extent. Thethe peptides. Infusion of the control peptide or solvents
salient observation made in the present study is thatdid not affect blood pressure (Fig. 8).
the administration of these connexin-mimetic peptidesWhen the experiments were conducted in the absence
in vivo substantially decreases basal renal blood flowof L-NAME and indomethacin, intrarenal infusion of
and increases systemic blood pressure. The results thus40Gap27 significantly decreased basal renal blood flow
suggest that gap junctional communication is essentialafter five minutes, with a recovery to baseline values
for EDHF-mediated signal transmission in the kidneyafter 30 minutes. Administration of the control peptide
in vivo, and provide compelling evidence to support adid not alter basal renal blood flow (Fig. 9). After infu-
role for EDHF in the control of blood pressure andsion of 40Gap27 without L-NAME and indomethacin, a
tissue perfusion.significant increase of mean arterial blood pressure was
Previous studies have shown that connexin-mimeticobserved, whereas blood pressure remained stable after
peptides are capable of interfering with EDHF-mediatedinfusion of the control peptide (Fig. 10).
The administration of connexin-mimetic peptides did signal transmission in rabbit thoracic aorta [20], rabbit
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Fig. 9. Renal blood flow (RBF) in baseline
conditions (), 5 min after intrarenal infusion
of a connexin-mimetic peptide () and 30 min
after the infusion of the peptide ( ). (A) 40Gap
27 peptide (N  6); (B) control peptide (N 
6). *P  0.01 vs. baseline values, #P  0.05
vs. 5 min after the peptide.
Fig. 10. Mean arterial blood pressure (BP) in
baseline conditions (), 5 min after intrarenal
infusion of a connexin-mimetic peptide (),
and 30 min after the infusion of the peptide
( ). (A) 40Gap 27 peptide (N 6); (B) control
peptide (N 6). *P 0.01 vs. baseline values,
#P  0.05 vs. 5 min after the peptide.
superior mesenteric artery [20, 22, 23], rabbit jugular Alternatively, myoendothelial gap junctions may be the
site of electrotonic propagation of hyperpolarizationvein [21], guinea pig carotid artery [24], rat hepatic and
mesenteric artery [24] and pig coronary artery [25]. In from the endothelial cells to the smooth muscle cells [4],
obviating the need for a chemical “EDHF.”all these studies 43Gap 27 peptide was used, thus sug-
gesting that connexin 43 is the most important connexin It should be noted that none of the gap junctional
blocking agents studied to date can discriminate betweenfor EDHF-mediated responses in these blood vessels. In
the present study of the rat renal microcirculation, 43Gap inhibition of myoendothelial gap junctions and inhibition
of gap junctional coupling within the endothelial or27 peptide only partially inhibited the L-NAME- and
indomethacin-resistant renal vasodilation in response to smooth muscle layers. It is usually assumed that gap
junction blockers affect transfer of an “EDHF” from theacetylcholine. However, 40Gap 27 peptide abolished the
response, supporting a more important role for connexin endothelium to smooth muscle cells via myoendothelial
gap junctions. An equally tenable assumption is that they40 in this vascular bed. Both 40Gap 27 and 43Gap 27
contain the motif SRPTEK present in the second extra- inhibit the propagation of hyperpolarization within the
endothelial or the smooth muscle cell layer.cellular loop of connexins 40 and 43. A control peptide,
with a replacement of two amino acids in this motif, was The exploration of the physiological role of EDHF
has been hampered by the absence of selective inhibitorsinactive, underlining the specificity of the results. The
acetylcholine response recovered to almost normal val- of EDHF that are suitable for in vivo use. Several groups
have expounded the hypothesis that EDHF may be aues 30 minutes after infusion of the 40Gap 27 and 43Gap
27 peptides, suggesting that binding is reversible and that back-up vasodilator mechanism in conditions with com-
promised bioavailability of NO [22, 31, 32]. It can bethe peptides are removed from the circulation, possibly
by glomerular filtration or degradation by proteases. questioned, however, whether such a complex and pow-
erful mechanism would have developed, only to serveNone of the peptides interfered with the responses to
DETA-NONOate, pinacidil and papaverine, indicating as a reserve vasodilator system. Pulsatile changes in in-
traluminal pressure induce the synthesis of EDHF, thespecificity for endothelium-dependent responses.
Although the present results and those of several in inhibition of which leads to a marked reduction in vascu-
lar compliance [33]. EDHF was found to play a rolevitro studies [19–25] support the involvement of gap
junctions in EDHF-mediated relaxations, the type of in the maintenance of basal perfusion pressure in the
perfused rat mesenteric arterial bed [34]. In other stud-information that passes through gap junctions remains
enigmatic. In view of the evidence that in some vascular ies, however, the removal of endothelium did not affect
the resting membrane potentials, suggesting that therebeds EDHF is a humoral substance, myoendothelial gap
junctions may represent its site of transfer from the endo- is no important tonic release of EDHF under basal condi-
tions, at least not in vitro [16]. Charybdotoxin and apa-thelium to the smooth muscle cells. Recently, strong
evidence implicated 11,12-EET as an EDHF in porcine min induced only a minor increase in resistance in the
isolated perfused hindlimb of eNOS knockout mice, ar-coronary arteries [6] and in hamster muscle resistance
arteries [7]. Also in renal arteries, it has been suggested guing against a significant basal release of EDHF in that
model [31]. The results of the present study stronglythat EETs may represent an EDHF [30]. EETs, however,
are hydrophobic and therefore in principle are not capa- support a tonic release of EDHF in vivo, with a modula-
tion of basal vascular tone. Administration of 40Gap 27ble of passing through the aqueous pore of gap junctions.
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